Pulmonary Edema Therapeutics Market Estimated to Witness Substantial Growth due to Rising Prevalence of Lung Related Disorders

Pulmonary edema refers to fluid accumulation in the air sacs of lungs which causes shortness of breath. It can occur due to heart failure, fluid overload, respiratory distress syndrome, pneumonia or other lung injuries. The commonly prescribed therapeutics include diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), statins, and vasodilators. These therapeutics aim to reduce pressure and fluid in the lungs.

The global pulmonary edema therapeutics market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The rising prevalence of lung diseases such as chronic obstructive pulmonary disorder (COPD), pneumonia, asthma and lung cancer is the major driver propelling the growth of pulmonary edema therapeutics market. As per the statistics of American Lung Association, COPD was the third leading cause of death in the United States in 2020, claiming more than 130,000 lives. Further, around 25 million Americans suffer from asthma which burden healthcare costs over $80 billion annually in the US. Diuretics are commonly used drugs to remove excess fluid from lungs in patients with pulmonary edema. Also, vasodilators are prescribed to reduce blood pressure and relieve strain on heart and lungs.

SWOT Analysis

Strength: Pulmonary edema therapeutics has a large patient population suffering from cardiac diseases and lung disorders. The availability of oral diuretics and intravenous vasodilators allows easy administration of drugs in serious conditions. Intensive research and development has improved the efficacy and safety of medications.

Weakness: High costs associated with innovative biologics and devices limit their widespread adoption. Dependence on symptomatic relief does not address the underlying cause in many patients. Side effects of pharmaceutical drugs reduce compliance and may worsen symptoms.

Opportunity: Rising instances of heart diseases, lung infections, and injuries provide scope for increased demand. Untapped rural markets in developing nations are opening up with improvements in healthcare infrastructure and spending. Personalized therapies tailored to genetic profiles can enable targeted interventions.

Threats: Patent expiries of blockbuster drugs enable entry of low-cost generics, compressing margins of innovators. Socialized medicine systems curb pricing ability while increasing regulatory expenses. Over-dependence on a few therapeutics raises supply concerns in case of production issues.

Key Takeaways

The Global Pulmonary Edema Therapeutics Market is expected to witness high growth over the forecast period of 2023 to 2030. The global pulmonary edema therapeutics market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030.

Regional analysis: North America currently dominates the pulmonary edema therapeutics market, supported by high healthcare expenditure and availability of advanced treatments. However, Asia Pacific is projected to showcase the fastest growth over the coming years due to rising investments to strengthen healthcare systems, large patient pools, and increasing standards of living. Rising access to insurance in middle-income countries like India and China will further fuel the expansion of therapeutic options in the region.

Key players: Key players operating in the pulmonary edema therapeutics market are Crayola LLC, Faber-Castell AG, Sargent Art, Reeves (Colart Group), Liquitex (Colart Group), Sax Arts & Crafts, Prang (Dixon Ticonderoga Company), RASCHER GmbH, Richeson Art Materials, and Jovi S.L. These companies have significant control over the value chain and focus on R&D to launch new proprietary drugs and combination therapies. Partnerships with regional pharma firms extend their geographical reach into high potential areas.

For more details on the report, Read- https://www.pressreleasebulletin.com/pulmonary-edema-therapeutics-market-size-and-share/